Letter to new registered shareholders and reply form
Filed with HKEX · Stock code 1093 · · 2 pages · English and Chinese
Pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the articles of association of the Company, the Company supplies Corporate Communications(Note 1) to shareholders of the Company (the “Shareholders”) (i) in printed form or (ii) by electronic means (other than Actionable (Note 2) Corporate Communications ) through the Comp
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- 2026 Interim report
- Voluntary announcement - phase II clinical trial of SYH2069 injection for the treatment of type 2 diabetes mellitus in adult patients officially initiated at the first centre in China
- Voluntary announcement - SYS6010 granted Breakthrough Therapy Designation by NMPA in China for the treatment of patients with actionable genomic alteration-negative non-squamous non-small cell lung cancer
- Voluntary announcement - phase i/ii clinical trial data of SYS6010 in combination with enlonstobart for the treatment of systemic treatment-naive, actionable genomic alteration-negative advanced nsclc orally presented at the 2026 world conference on lung cancer (wclc)
- Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
Later from CSPC Pharmaceutical
- Notification letter to non-registered holder and request form
- Notification letter to shareholder and change request form
- Voluntary announcement - phase III clinical trial of docetaxel for injection (albumin-bound) (HB1801) for the treatment of advanced breast cancer officially initiated in china
- Voluntary announcement - phase III clinical trial of becotatug (JMT101) in combination with osimertinib for the first-line treatment of locally advanced or metastatic NSCLC harbouring EGFR exon 20 insertion mutations achieves positive topline results
- Voluntary announcement - SYS6077 injection obtains clinical trial approval in China
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical